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Abstract 
Background: The plasma-derived atherogenic index (AIP) is associated with an increasing 
risk for cardiovascular diseases. Whether an increased AIP may predict the complexity of 
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percutaneous coronary intervention (PCI) of chronic total occlusion (CTO), according to 
available research, has never been investigated before.  
Methods: 317 patients were included prospectively and treated with PCI for at least one CTO 
between 2012 and 2017. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) 
plasma levels were measured 24 h before PCI. All patients were stratified into tertiles of AIP 
(defined as 0.11, 0.11–0.21, > 0.21) based on their TG/HDL-C (AIP) levels.  
Results: Mean AIP of all patients undergoing CTO-PCI was 0.53 ± 0.29. The majority of 
patients were male (82.6%), and mean age was 61 ± 10.4 years. Increased AIP > 0.21 was 
associated with longer occlusion length (statistical trend p = 0.082) and stent routes (p = 
0.022) and with a higher number of implanted stents (n > 4) (statistical trend p = 0.072). 
Success rates were similar in all AIP categories (p = 0.461). In-hospital PCI-related 
complications were rare and not statistically different (p = 0.852).   
Conclusions: This  study demonstrates for the first time that an increased AIP may predict the 
complexity of CTO-PCI and additionally may help to improve planning and quality of CTO-
PCI. 
Key words: atherogenic index, chronic total occlusion (CTO), coronary artery disease, 
percutaneous coronary intervention (PCI) 
 
 
Introduction 
Recanalization of chronic total occlusion (CTO) still remains a challenging procedure 
in interventional cardiology. A CTO of a coronary artery can be identified in up to 18% 
among patients with a clinical indication for coronary angiography. With the advent of novel 
recanalization techniques and emerging devices, percutaneous coronary intervention (PCI) 
has become promising leading treatment option for these patients [1–5].   
The atherogenic index of plasma (AIP), the logarithm of molar ratio of triglyceridemia 
(TG) to high-density lipoprotein cholesterol (HDL-C) has been established as one marker to 
predict plasma atherogenicity and coronary artery disease (CAD) [8, 9]. Although some lipid 
variables were associated with the extent of CAD, the specific ratio of TG to HDL-C ratio 
showed the strongest association respectively. Variation of TG/HDL-C ratio may also be 
more associated with substantial alterations in metabolic indices predictive for increasing risk 
of ischemic heart disease compared to variation of low-density lipoprotein cholesterol (LDL-
3 
 
C)/HDL-C ratio [10, 11]. Is has been shown recently that AIP may reveal highest sensitivity 
for predicting acute coronary events [23]. 
Within this context, this study assessed the association between AIP, as a major risk 
factor of CAD, and CTO and CTO-PCI, as a complex coronary intervention. 
 
Methods  
Between 2012 and 2017, a total of 317 patients undergoing CTO-PCI in a German 
high volume CTO center. All patients had a clinical indication for CTO-PCI and/or positive 
functional ischemia test assessed by magnetic resonance imaging (MRI) or stress-
echocardiography in the territory of the occluded coronary artery. 
All procedures were performed via femoral access using 7-french guiding catheters; in 
the majority of patients contralateral injections of contrast were performed to determine the 
length of the lesion and the existence and extent of collateral connections. Decisions to treat 
patients either by antegrade or retrograde CTO-PCI techniques was based on operator 
discretion. To prevent thrombembolic complications heparin was administered intravenously 
during CTO-PCI, guided by activated clotting time (> 300 s). 
The J-CTO score, combining several parameters of CTO including the degree of 
calcification of lesion, bending > 45° in CTO segment, blunt proximal cap, length of occluded 
segment (> 20 mm) and a previously failed recanalization attempt, was calculated for all 
patients [21].  
After PCI a dual antiplatelet therapy consisting of 100 mg of aspirin once daily 
indefinitely and 75 mg of clopidogrel once daily for at least 6 months was continued. 
Procedural success was defined as successful recanalization of CTO with a residual stenosis < 
30% and restoration of thrombolysis in myocardial infarction (TIMI)-flow grade 3.  
A composite safety endpoint summarizing severe complications such as all-cause 
mortality, vessel perforation, myocardial infarction (MI) and thrombembolic events was 
evaluated for all patients. 
Triglycerides and HDL-C levels were measured after taking venous blood samples in 
EDTA tubes 24 h before the procedure. Analysis of plasma or serum total cholesterol (TC) 
and HDL was measured directly in serum while TG were measured enzymatically in serum or 
plasma [20]. TG/HDL-C was calculated as TG (mmol/L) divided by HDL-C (mmol/L). The 
patients were separately grouped into tertiles based on TG/HDL-C levels. It has been 
demonstrated before that an AIP value of under 0.11 is associated with low risk of 
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cardiovascular disease (CVD); the values between 0.11 to 0.21 and upper than 0.21 are 
associated with intermediate and increased risks, respectively [8, 9].  
 
Statistical analysis 
The distribution of continuous variables is characterized by mean ± standard deviation, 
or median and minimum–maximum, the distribution of categorical variables by absolute and 
relative frequencies. 
The Shapiro-Wilk test was used to test for normality of data. The differences of 
distributions of continuous variables between three AIP categories were tested with the 
Kruskal–Wallis Test (rejected normality) or F Test. Differences in distributions of categorical 
variables were tested using the Fisher exact test. 
According to the exploratory character of analysis all p values were interpreted as 
descriptive measures rather than as definitive inferential measures. 
 
Results 
The overall procedural success rate was 86% which is in accordance with actual trials. 
The majority of the patients were male (82.6%), and the mean age was 61 ± 10.4 years. The 
mean AIP of all patients was 0.53 ± 0.29; male patients were younger than women (60.3 ± 
10.2 years vs. 64.6 ± 10.7 years; p < 0.005). 92% of patients were already under medication 
with CSE inhibitors. No differences were found between patients with CSE inhibitor to those 
without CSE in this study population. 
Figure 1 shows a disproportionate distribution of AIP categories in the present cohort. 
Only 5% of patients (n = 16) had a normal AIP level of < 0.11. Table 1 presents baseline 
characteristics of the patients studied, and are classified by AIP categories.  
Patients with an AIP > 0.21 were more frequent male (p = 0.075) and had a higher 
body mass index (BMI) (p = 0.023). They also had a higher LDL-C (p = 0.043) and suffered 
more frequently from arterial hypertension (p = 0.084). There was an increase of frequency of 
diabetes mellitus (DM), BMI, smoking and family history of CAD alongside an increase in 
AIP. In summary, these cardiovascular risk factors were associated with a high AIP.   
This increase was also seen for some peri-procedural characteristics as shown in Table 
2.   
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A high AIP > 0.21 was associated with longest occlusions (statistical trend p = 0.082), 
the longest stent routes (p = 0.022; Table 1) and highest number of the implanted stents (n > 
4) after successful recanalization (statistical trend p = 0.072) (Table 2). Although the J-CTO 
score — representing the complexity of the CTO lesion — was related to a high AIP (p = 
0.015; Fig. 2), procedural variables such as amount of contrast medium, examination time and 
fluoroscopy time were independent of the extent of AIP.  
A majority of patients suffered from a multi-vessel coronary disease; 38.8% had 
coronary 2-vessel disease and 32.2% coronary 3-vessel disease. 
No differences in procedural success rates in different AIP categories was shown (p = 
0.461). In-hospital, acute procedural complications were rare and showed no statistically 
significant difference (p = 0.852). They included mostly vascular complications such as a 
local hematoma at puncture site (n = 19) and one cardiac tamponade which could be treated 
with a pericardiocentesis without further consequences. No severe complications such as peri-
procedural death or ST-elevation myocardial infarction occurred. 
 
Discussion 
Dyslipidemia is an established risk factor for CVD in the general population.  
The AIP, which was first described by Dobiášová and Frohlich in 2001 [8], is a 
comprehensive lipid index, and a strong marker for predicting risk of CAD. In this 
retrospective study, we examined the association between AIP and patients with CTO and 
CTO recanalization, respectively. According to available research, no data are available in the 
current literature about this issue. 
The present data emphasizes several important aspects. First, we did show that AIP 
may predict complexity of a CTO, evaluated by J-CTO score, including severe calcification, 
tortuosity, stump morphology and lesion length. Second, it could demonstrated that AIP is 
associated with peri-procedural characteristics such as number and length of stents after a 
successful recanalization. Third, it was confirmed that AIP is closely related to several 
cardiovascular risk factors including male gender.  
These findings are in accordance with previous trials, showing a strong association 
between AIP, cardiovascular risk factors and severity of CAD [9, 11]. Therefore Niroumand 
et al. [9] has suggested that AIP could be used as a regular monitoring index of CAD in every 
day practice, while Wan et al. [12] proved that an elevated AIP is a powerful independent 
predictor of all-cause mortality and for subsequent CVD after coronary revascularization [12]. 
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Lee et al. [13] confirmed prognostic relevance of AIP within a nationwide prospective cohort 
including more than 1,000 patients with a terminal renal failure. Furthermore Shimizu et al. 
[18] found a significant positive correlation between diabetes mellitus and AIP and as well as 
with carotid intima-media thickness (cIMT), progression and arterial stiffness. 
An explanation may be the association of AIP with LDL-C particle size, insulin 
resistance and metabolic syndrome [8, 14–16]. Hermans et al. [17] demonstrated a 
relationship between AIP and vascular damage and an association with residual vascular risk, 
beta-cell function loss and microangiopathy in diabetic patients.  
The present study observes that patients with a higher BMI revealed an increased AIP 
(p = 0.023). These findings are in agreement with previous data that proved close association 
between abnormalities of blood lipoproteins and habits of people, such as life style and eating 
habits [9, 25, 26].  
Higher AIP correlates with a higher J-CTO Score, but failed to shown as a predictor 
for procedural success in CTO recanalization. Lemieux et al. [10] proved that in predicting 
CAD the AIP is superior to other indices like TC/HDL-C ratio and LDL-C/HDL-C ratio [10]. 
Furthermore Yildiz et al. [19] suggested that AIP might be a method which can be used for 
both diagnosis of subclinical atherosclerosis and in deceleration processes of its progression.  
The fact that the AIP is associated with male gender in this study (p = 0.075) is in 
accordance with a large chinese cohort with over 430 patients which showed increased AIP 
being independently associated with coronary heart disease in Chinese males [24].  
The AIP may be helpful  to estimate the complexity of the procedure in advance and to 
make a decision on this basis. It is also easy to calculate and may be included in daily clinical 
practice. Unfortunately it could not demonstrated that this index can predict possible 
complications related to the complex coronary intervention of CTO-PCI. Gritzenko et al. [22] 
pointed out that AIP may be necessary to risk assessment before PCI and CABG. In a trial of 
186 patients it was shown that this index can significantly predict re-stenosis after CABG and 
PCI.  
 
Limitations oft he study 
The present study is a retrospective analysis and all data are collected from a single-
center. The results of this study may have been influenced by selection criteria, operator 
experience, and varying techniques used by operators. Furthermore, there was no data about 
the impact of long term follow-up of AIP in CTO patients. Another limitation may be that the 
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matched and un-matched data used in this study were already collected. Thus, the analysis 
represents an observational character only. 
 
Conclusions 
The TG/HDL-C ratio may be an independent predictor for complexity of a CTO. 
Prospective evaluation of AIP as a determinant of the lesion may add adjunctive information 
for procedural planning of intervention. 
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Table 1. Baseline and periprocedural characteristics of the study patients, classified by atherogenic index 
categories. 
 
*Median (min–max); BMI — body mass index; CABG — coronary artery bypass graft surgery; CAD — 
coronary artery disease; COPD: chronic obstructive pulmonary disease; CTO — chronic total occlusion; LDL-C 
— low density lipoprotein cholesterol; LVEF — left ventricular ejection fraction; MI — myocardial infarction; 
PCI — percutaneous coronary intervention  
Variable < 0.11 0.11–0.21 > 0.21 P 
Number 16 20 281  
Age [years]* 62 (37–86) 61 (39–81) 61 (33–87) 0.870 
Male gender 68.8% (11)  70.0% (14) 84.3% (237) 0.075 
BMI [kg/m²]* 26.0 (21–39) 27.0 (19–35) 27.4 (17–45) 0.023 
Diabetes mellitus  18.8% (3) 30.0% (6) 24.6% (69) 0.742 
Smoking  25.0% (4) 30.0% (6) 46.6% (131) 0.101 
COPD 6.3% (1) 15.0% (3) 7.1% (20) 0.377 
LDL-C > 100 mg/dL  18.8% (3) 50.0% (10) 50.5% (142) 0.043 
Hypertension  56.3% (9) 75.0% (15) 79.4% (223) 0.084 
Family history of CAD  12.5% (2) 25.0% (5) 27.4% (77) 0.446 
Prior MI  6.3% (1) 30.0% (6) 28.8% (81) 0.139 
Prior CABG  12.5% (2) 0.0% (0) 13.2% (37) 0.245 
Prior CTO-PCI attempt  37.5% (6) 35.0% (7) 49.8% (140) 0.325 
Prior PCI  37.5% (6) 30.0% (6) 40.2% (113) 0.706 
LVEF ≥ 40  93.8% (15) 100% (20) 97.5% (274) 0.403 
Amount of contrast 
medium [mL]* 
220.9 (90–500) 226.8 (90–600) 228.2 (70–600) 0.736 
Examination time 
[min]* 
108.4 (45–180)  95.3 (30–220) 110.9 (15–300) 0.110 
Fluoroscopy time 
[min]* 
37.4 (11–76) 34.9 (4–94) 37.6 (7–104) 0.476 
Lenght of occlusion 
[mm]* 
32.8 (15–70) 29.5 (15–70) 37.6 (10–100) 0.082 
Stent diameter [mm]* 3.0 (2.5–3.5) 2.9 (2.5–3.5) 3.1 (2.25–4.0) 0.122 
Lenght of stent [mm]  61.0 (23–119) 52.2 (18–104) 69.1 (12–157) 0.022 
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Table 2. Angiographic characetristics and procedural outcome, classified by median 
atherogenic index. 
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CTO — chronic total occlusion; J–CTO — japansese chronic total occlusion; LAD — left anterior descending; 
LCX — left circumflex; RCA — right coronary artery 
 
 
FIGURES LEGEND 
Figure 1. Distribution of atherogenic index (AIP) categories. 
Figure 2. Atherogenic index (AIP) in J-CTO score categories. 
 
Variable N Mean AIP P 
CTO in: 
LAD  
LCX  
RCA 
 
87 
32 
197 
 
0.511  
0.564 
0.528 
0.862 
Coronary vessel disease 
1 
2 
3  
 
93 
123 
102 
 
0.522 
0.513 
0.556 
0.535 
Blunt stump/no stump 215 0.536 0.483 
Tortuosity > 90° 226 0.538 0.315 
Severe calcification 248 0.538 0.208 
J-CTO Score: 
0  
1 
2 
3 
4 
5 
 
9 
28 
56 
77 
108 
39 
 
0.358 
0.366 
0.587 
0.539 
0.558 
0.502 
0.015 
Retrograde approach 80 0.596 0.015 
Drug eluting stents 270 0.525 0.662 
Number of stents: 
0 
1 
2 
3 
≥4 
 
36 
53 
117 
77 
25 
 
0.545 
0.424 
0.553 
0.531 
0.578 
0.072 
Success 272 0.524 0.461 
Complications 20 0.531 0.852 


